Dexcom G7 15-Day Continuous Glucose Monitor Authorized by Health Canada, Stelo CGM Cleared for Pediatric OTC Use by U.S. FDA

July 19, 2026

Business Wire, MarketScreener, CureCapture, Oura Member Care USA, Canada

Overview

Dexcom’s G7 15-day continuous glucose monitoring (CGM) system has received Health Canada authorization for adults aged 18 and older, extending wear time to 15.5 days with an 8.0% MARD. Concurrently, the U.S. FDA cleared the Dexcom Stelo Glucose Biosensor System for over-the-counter (OTC) use in children aged two and older who do not use insulin, significantly broadening CGM accessibility. This dual advancement streamlines diabetes management for Canadian adults and introduces a crucial OTC option for pediatric non-insulin users in the U.S., with Oura app integration further enhancing data accessibility for comprehensive health insights.

In Depth

Key Findings

Dexcom has announced that its G7 15-Day Continuous Glucose Monitoring (CGM) System has received authorization from Health Canada for use in adults aged 18 and older. This extends the sensor’s wear duration to 15.5 days, a significant improvement over the standard 10 days, while maintaining a robust overall Mean Absolute Relative Difference (MARD) of 8.0%. This authorization is poised to enhance glucose management continuity and reduce the burden of frequent sensor changes for Canadians living with diabetes.

In a parallel development, the U.S. Food and Drug Administration (FDA) has cleared the Dexcom Stelo Glucose Biosensor System for over-the-counter (OTC) use in children aged two and older who do not use insulin. This marks the first OTC CGM specifically for this pediatric demographic, making real-time glucose monitoring more accessible for families without requiring a prescription from a healthcare provider. The clearance is a pivotal step in expanding early glucose trend awareness and promoting proactive health management in younger non-insulin-using populations.

Furthermore, Oura, a leading wearable smart ring company, has confirmed integration of the Stelo Glucose Biosensor with its application. This allows Oura users to view their Stelo glucose data directly within the Oura app, alongside other physiological metrics like sleep, activity, and heart rate. This integration exemplifies the growing trend of digital health ecosystems leveraging diverse data streams for a more holistic view of individual health.

Technical & Clinical Details

Dexcom G7 15-Day System: The extended 15.5-day wear time represents an engineering advancement aimed at improving user convenience and adherence. The 8.0% MARD ensures high accuracy, critical for reliable glucose management. The system maintains its compact, all-in-one sensor design, facilitating easier application and discreteness.
Stelo CGM (Pediatric OTC): Designed for individuals not using insulin, Stelo focuses on understanding how diet and activity influence glucose levels rather than managing acute hypoglycemic events. Its OTC clearance for children addresses an unmet need, providing a tool for early detection of glucose dysregulation and encouraging healthier lifestyle choices from a young age.
Oura App Integration: The integration allows for a seamless flow of glucose data from Stelo into the Oura app. Users can overlay glucose trends with other biometric data, enabling sophisticated analysis of how daily habits impact glycemic response. This data-driven approach supports personalized health interventions and empowers users with actionable insights.

Background & Industry Context

The continuous glucose monitoring market is experiencing rapid growth, driven by increasing diabetes prevalence and continuous innovation. Extended wear times and OTC accessibility are key factors accelerating CGM adoption by improving user convenience and reducing barriers to entry. The convergence of CGM technology with broader digital health platforms underscores a paradigm shift towards integrated, proactive, and personalized healthcare solutions.

These approvals reinforce Dexcom’s leadership position in the global CGM market, providing a competitive edge against rivals like Medtronic and Abbott. The strategic expansion into the pediatric OTC segment for Stelo is particularly significant for future market development and long-term user acquisition. The broader industry trend is towards less invasive, more user-friendly, and highly connected health monitoring devices.

Strategic Significance & Outlook

Looking forward, Dexcom is expected to pursue further regulatory approvals for the 15-day G7 system in other international markets and to expand the availability of Stelo. The integration with consumer wearables like Oura is crucial for reaching a wider audience, including individuals at risk of diabetes or those seeking to optimize their metabolic health proactively. Future developments may include enhanced AI-driven analytics within these platforms, offering personalized recommendations for diet, exercise, and lifestyle modifications based on real-time and historical data. This ongoing evolution will solidify biosensors as indispensable tools in both clinical diabetes management and general wellness.

Source: https://www.businesswire.com/news/home/20260713506385/en/Dexcom-G7-15-Day-Receives-Health-Canada-Authorization-Extending-Wear-and-Continuity-for-Canadian-Adults-Living-with-Diabetes

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.